Elaine Chen on Muck Rack

Elaine Chen

  • Executive Director, ElevAAte Biotech
As seen in: MSN, The New York Times, The New York Times en Español, HuffPost, Nature, The Economic Times, Yahoo News, Canadian Broadcasting Corporation (CBC), TechCrunch, WIRED Magazine and
Into community engagement and citizen science. Before @nytimesEvents, @WNYC, and @nycgov. 🇹🇼
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elaine

Contact Elaine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Biogen to acquire immunology biotech Apellis for $5.6 billion

|
By Elaine Chen
| The Boston Globe
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Biogen said Tuesday that it would buy Apellis Pharmaceuticals for an upfront payment of around $5.6 billion, expanding its portfolio with a set of approved immunology drugs. Cambridge-based Biogen will acquire Apellis, headquartered in Waltham, for $41 per share, more than double the latter’s closing price on Monday.
Open in Who Shared Issue with article?

What to know about TrumpRx

|
By Elaine Chen, John Wilkerson , Chelsea Cirruzzo 
| The Boston Globe
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. President Trump on Thursday night announced the launch of TrumpRx, the website that he and his aides have touted for months as a platform aimed at lowering prescription drug prices.
Open in Who Shared Issue with article?

The best and worst drug names of 2025

|
By Elaine Chen
| The Boston Globe
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. As if news outlets didn’t bombard you with enough end-of-year lists, I’ve decided to start a new tradition: compiling the best and worst new drug names of 2025. I picked some nominees from the list of novel drugs approved in 2025 and asked my STAT colleagues to vote.
Open in Who Shared Issue with article?
See all 709 licensed articles (766 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Elaine

Contact Elaine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified